

Article



# Immunomodulatory Properties of Adipose-Derived Stem Cells Treated with 5-Azacytydine and Resveratrol on Peripheral Blood Mononuclear Cells and Macrophages in Metabolic Syndrome Animals

Katarzyna Kornicka<sup>1</sup>, Agnieszka Śmieszek<sup>1</sup>, Agnieszka Sławomira Węgrzyn<sup>2</sup>, Michael Röcken<sup>3</sup> and Krzysztof Marycz<sup>1,3,\*</sup>

- <sup>1</sup> Department of Experimental Biology, The Faculty of Biology and Animal Science, University of Environmental and Life Sciences Wroclaw 50-375, Poland; kornicka.katarzyna@gmail.com (K.K.); smieszek.agnieszka@gmail.com (S.A.)
- <sup>2</sup> PORT Polish Center for Technology Development, Wrocław 54-066, Poland; agnieszka.wegrzyn@eitplus.pl
- <sup>3</sup> Faculty of Veterinary Medicine, Equine Clinic-Equine Surgery, Justus-Liebig-University, Giessen 35392,
- Germany; Michael.Roecken@vetmed.uni-giessen.de \* Correspondence: krzysztofmarycz@interia.pl

Received: 24 August 2018; Accepted: 8 October 2018; Published: 24 October 2018

Abstract: Endocrine disorders, including equine metabolic syndrome (EMS), are a serious issue in veterinary medicine and horse breeding. Furthermore, EMS was shown to affect the cytophysiological properties of adipose-derived stem cells, reducing their therapeutic potential. However, it was shown that those cells can be rejuvenated while using a combination of two chemicals: 5-azacytydine (AZA) and resveratrol (RES). In the present study, we decided to evaluate the immunomodulatory properties of AZA/RES-treated adipose-derived stem cells (ASC) isolated from EMS horses (ASCEMS). Thus, we co-cultured ASC with peripheral blood mononuclear cells (PBMC) and RAW264.7 macrophages. Most attention was placed on regulatory T lymphocytes (TREG), as well as the messenger RNA (mRNA) and protein levels of several cytokines (tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ), interleukin (IL)-6, IL-10, and IL-1 $\beta$ ). Moreover, we also investigated the expression of genes related to auto- and mitophagy in both PBMCs and ASCs. PBMCs were obtained from healthy and EMS-suffering individuals and were co-cultured with ASCs that were isolated from healthy and EMS horses cultured in control conditions and with AZA/RES. We discovered that cells treated with AZA/RES increase the TREG number while co-cultured with PBMCs. Moreover, the co-culture of PBMCs with AZA/RES-treated ASCEMS induced mitophagy in PBMCs. Furthermore, ASCEMS pre-treated with AZA/RES displayed anti-inflammatory properties, as decreased levels of TNF- $\alpha$ , nitric oxide (NO), and IL-6 were observed in those cells in comparison with their untreated counterparts in the co-culture with RAW264.7 macrophages. In summary, we demonstrated that ASCEMS treated with AZA/RES displayed increased anti-inflammatory properties, and was able to regulate and activate the TREG-related anti-inflammatory response.

**Keywords:** adipose-derived stem cells; mesenchymal stem cells; inflammation; autophagy; immunomodulatory effects

# 1. Introduction

Mesenchymal stem cells (MSCs) are a progenitor stem-cell population isolated from multiple tissues, mainly bone marrow (BMSC) and adipose tissue (ASC). Adipose tissue is the favored source

of MSCs because it is accessible in vast amounts and it results in a high yield of isolated cells. ASCs can differentiate into chondrocytes, adipocytes, and osteoblasts, and they display a wide range of immunomodulatory functions, which makes them a valuable tool in cell-based therapies. Furthermore, MSCs are characterized by low immunogenicity and immunoregulatory properties [1]. For these reasons, the application of MSCs in the treatment of autoimmune disorders and tissue damage, and in the induction of allogenic transplant tolerance is fully reasonable and promising [2,3]. MSCs are able to escape immune surveillance and induce allogeneic tissue repair due to the low expression of major histocompatibility complex 1 (MHC-I) antigens, and the lack of major histocompatibility complex 2 (MHC-II), cluster of differentiation 40 (CD40), CD80, and CD86 expressions [4]. However, it was shown that, during in vivo differentiation, the expression of MHC antigens is triggered, although they are not rejected by host organism [5]. The mechanism underlying that phenomenon is still poorly understood. Multiple studies indicated that MSCs regulate T-cell and B-cell functions. They suppress T-cell proliferation and cytokine secretion, and they regulate the T helper 1/T helper 2 (Th1/Th2) cell balance [6,7]. Moreover, they are able to regulate the functions of regulatory T cells (TREG) [8], which indicates that MSCs may represent an effective therapeutic strategy for metabolic syndrome treatment.

Equine metabolic syndrome (EMS) is a disorder that is more and more often diagnosed in horses which threatens animal life, as it usually leads to laminitis. EMS is similar to metabolic syndrome in humans (MS) as it is characterized by insulin resistance, visceral obesity, hypertriglyceridemia, and low high-density lipoprotein (HDL) cholesterol levels. Metabolic overload triggers multiple stress reactions in horses suffering from EMS, including oxidative, inflammatory, and organelle stresses in the liver, muscles, and adipose tissue [9]. All of these factors contribute to the pro-inflammatory state of the organism. It was shown that interleukin-1 $\beta$  (IL-1 $\beta$ ), interleukin-6 (IL-6), and tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ) gene expressions were lower or not different in obese, hyperinsulinemic horses compared with animals of normal weight [10]. On the other hand, in EMS horses, no differences were found in the TNF- $\alpha$ , IL-1 $\beta$ , IL-6, plasminogen activator inhibitor 1 (PAI-1), and monocyte chemoattractant protein 1 (MCP-1) expressions in different fat depositions [11]. On the other hand, another study indicated that a positive correlation of TNF and IL-1 expressions, body condition score (BCS), and increased cytokine expression are major risk factors for the development of insulin resistance in horses [12]. Our own previous data showed that IL-6 expression in adipose tissue biopsies that are derived from animals with EMS was enhanced, while TNF- $\alpha$  levels of both groups were comparable. Moreover, EMS horses displayed significantly increased levels of serum IL-6 and TNF- $\alpha$ . Furthermore, histological analysis revealed macrophage infiltration and fibrosis in adipose tissue samples from EMS animals.

The importance of the cytokine profile and its role in the development/maintenance of EMS, due to discrepancies in different research studies, are widely and controversially discussed. However, no data exist regarding the contribution of ASC to inflammation and reduced insulin response in tissues in the course of EMS. As ASCs reside in the pro-inflammatory microenvironment of adipose tissue, they may indeed contribute to or restrict the development of EMS due to their immunoregulatory properties. For this study, we postulated that ASCs from EMS (ASCEMS) are not as effective in immunomodulation as ASCs from healthy individuals. Our own previous studies revealed that ASCEMS cells are characterized by decreased viability, senescence, apoptosis, and decreased multipotency capacities in comparison to healthy animals [13–15].

For that reason, those cells may also present different behavior in vivo, including a diminished anti-inflammatory response.

Taking into consideration the impairment of ASCEMS cells, in the present study, we decided to rejuvenate those cells in vitro and investigate how this influences their immunomodulatory properties. We treated cells with a combination of 5-azacytydine (AZA) and resveratrol (RES) in order to reverse epigenetic alternations and to reduce the accumulation of oxidative stress factors. Our previous data showed that the application of AZA in human ASCs that were isolated from elderly patients improved their proliferation and reduced apoptosis [16]. Similar results were found for RES, as we showed that polyurethane–polylactide-based material doped with resveratrol decreased the

senescence and oxidative stress of ASCs [17]. We hypothesize that autophagy is a mechanism underlying the immunoregulatory properties of ASCs. Autophagic machinery is triggered in stress conditions in order to ensure cell survival. It involves the degradation of cellular components, misfolded proteins, and impaired organelles, delivering valuable building blocks for the synthesis of indispensable biomolecules. Moreover, it plays a crucial role in the regulation of lymphocyte homeostasis and survival, cytokine secretion, and antigen presentation [18]. However, whether autophagy plays a role in regulating ASC-mediated immunomodulation remains elusive.

Based on these observations, in the present study, we decided to investigate whether the treatment of adipose stem cells that were isolated from equine metabolic syndrome individuals with AZA/RES influences their immunogenic properties and immunomodulatory mechanisms in order to provide novel data for the clinical application of rejuvenated cells. To test this hypothesis, we co-cultured ASCEMS and ASCAZA/RES with peripheral blood mononuclear cells (PBMC) and RAW264.7 macrophages.

#### 2. Materials and Methods

All of the reagents used in this experiment were purchased from Sigma-Aldrich (Poland), unless indicated otherwise.

#### 2.1. Qualification of Horses

Twelve mixed-sex, age-matched (9–14 years; mean  $\pm$  SD, 11.2  $\pm$  1.7 years) horses, were divided into two groups: a group of individuals suffering from EMS (n = 6) and the control group, consisting of animals in good physical condition (n = 6), as shown previously [19]. The division was done on the basis of detailed interviews with owners and clinical parameters, such as body weight, body condition score, cresty neck score, combined glucose-insulin test, leptin concentration, and insulin levels. Experimental procedures were approved by the II Local Ethics Committee of Environmental and Life Sciences University (Chelmonskiego 38C, 51-630 Wroclaw, Poland; decision No. 84/2012; extension No. 84/2018).

#### 2.2. ASC Isolation and Culture

ASC were isolated from subcutaneous adipose tissue (from the tail base of horses). Tissue specimens were washed with a Hank's balanced salt solution (HBSS) supplemented with 1% of a penicillin, streptomycin, and amphotericin B (PSA, 10,000 units penicillin, 10 mg streptomycin, and 25  $\mu$ g amphotericin B per mL) solution and minced into small pieces. Next, samples were digested with collagenase type I (1 mg/mL) for 40 min at 37 °C. Obtained suspension was centrifuged at 1200 × g for 10 min at 23 °C, then pellets were re-suspended in the culture medium and transferred to the culture flasks. Prior experiments, ASC from experimental group were treated for 24 h with combination of AZA (0.5  $\mu$ M) and RES (0.05  $\mu$ M) diluted in water.

Cultures were maintained under constant conditions at 37 °C, 95% humidity, and 5% CO<sub>2</sub>. The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) low glucose supplemented with 10% of fetal bovine serum (FBS) and 1% PSA solution. Medium was changed every two days. After reaching 80–90% of confluence, the cells were passaged using a trypsin solution (TrypLE Express, Life Technologies, Carlsbad, CA, USA). At passage 3, MSCs were collected and cellular phenotype confirmed by the expression of markers CD<sub>44</sub>, CD<sub>90</sub>, and CD<sub>45</sub>, as well as by their capacity for trilineage differentiation, as previously shown [19].

#### 2.3. Extraction and Culture of Peripheral Blood Mononuclear Cells (PBMC)

Fresh blood was collected from horses into syringes filled with heparin. PBMCs were isolated using Ficoll Histopaque®-1077 density gradient centrifugation at 400× *g*, at 4 °C for 20 min. Cells from buffy coat layer were collected and washed three times with HBSS. Next, cells were re-suspended in one complete culture medium (RPMI 1640 medium supplemented with 10% FBS, 1% PSA) and transferred to culture dish.

# 2.4. Flow Cytometry Analysis

PBMCs isolated from horses were stained against CD<sub>4</sub> and CD<sub>25</sub>. Briefly, cells were incubated with mouse anti horse CD<sub>4</sub> (MCA1078GA, 1:200; Abd Serotec, Hercules, CA, USA) in 4 °C for 30 min. Next, cells were washed three times and incubated with secondary antibody (A-31571, 1:1000; Alexa Fluor Plus 647 Thermo Fisher Scientific, Carlsbad, CA, USA). Following this, cells were stained with mouse anti-human CD<sub>25</sub> conjugated with FITC (MA1-35144, 1:200; Thermo Fisher Scientific, Carlsbad, CA, USA). The same procedure was applied to PBMC after co-culture with ASCs. After last staining, cells were washed cells and resuspended in PBS. The measurements were performed using BD LSR Fortessa (Becton-Dickinson and Company, Franklin Lakes, NJ, USA). At least 20,000 cells were analysed. The data analysis was performed using FlowJo software (TreeStar Inc., Ashland, OR, USA). The first gate include lymphocytes, which were than gated and analysed for CD<sub>4</sub> expression. Further the CD<sub>4</sub><sup>+</sup> population was analysed for the expression of CD<sub>25</sub>. Additionally, within the population of CD<sub>4</sub><sup>+</sup>/CD<sub>25</sub><sup>+</sup> cells, we gated the population with the distinct brighter fluorescence signal i.e., CD25<sup>high</sup> cells.

#### 2.4.1. ASC-PBMC Co-Culture

ASCs were seeded on 24-well plates at the density of  $4 \times 10^4$  24 h prior co-culture with PBMCs. Cells were cultured in DMEM-LG supplemented with 10% FBS and 1% PSA. The isolated PBMCs (5 × 10<sup>5</sup> cells/well) were seeded onto 8 µm transwell and co-cultured with pre-seeded ASC. After 24 h the supernatant was collected for further analysis and cells were lysed in TRI Reagent.

#### 2.4.2. ASC-RAW264.7 Co-Culture

RAW 264.7 were counted and seeded at the density of  $1 \times 10^6$  cells/mL per well of 24-well plate in a volume of 500 µL/well. After 18 h, non-adherent cells were removed by a gentle wash with warm HBSS. Next, LPS was added to the culture media at a concentration of 1 µg/mL. At the same time, ASC in the amount of  $4 \times 10^4$  was added to culture wells. After 24 h of co-culture, media were collected for an analysis of the macrophages' secretory activity, and the cells were lysed by adding TRI Reagent.

#### 2.5. Nitric Oxide (NO) and Superoxide Dismutase (SOD) Levels Analysis

SOD activity analysis was conducted using a SOD Assay Kit, and the level of nitric oxide (NO) was assessed with a Griess reagent kit (Life Technologies, Carlsbad, CA, USA). All of the procedures were performed in accordance to manufacturer's instructions.

#### 2.6. Real-Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR)

Total RNA was isolated from cells according to a single-step method that was described previously by Chomczynski and Sacchi [20] and Reverse Transcription Polymerase Chain Reaction (RT-PCR) was performed as described elsewhere [14]. RNA quality and quantity were determined with spectrophotometry (Epoch, BioTek, Winooski, VT, USA). 150 ng of total RNA was used for genomic DNA digestion and cDNA synthesis. Digestion of genomic DNA was performed using DNase I, RNAase-free (Life Technologies) while complementary DNA (cDNA) synthesis were performed using RevertAid RT Reverse Transcription Kit (Life Technologies). For each reaction, 150 ng of total RNA was used. Genomic DNA digestion and cDNA synthesis were performed using a T100 Thermal Cycler (Bio-Rad, Hercules, CA, USA). The qRT-PCR reactions were carried out using a SensiFAST SYBR Green Kit (Bioline, London, UK). Primer concentration equalled 0.5  $\mu$ M. Sequences of the primers that were used in reactions are listed in Table 1. All qRT-PCR reactions were conducted with CFX Connect<sup>TM</sup> Real-Time PCR Detection System (Bio-Rad). Relative gene expression analysis (Qn) were evaluated in relation to the GAPDH as a housekeeping gene using  $\Delta\Delta$ Ct method. Moreover, the ratio of MFN/FIS expression was determined by dividing  $\Delta\Delta$ Ct of genes.

Gene	Primer	Sequence 5'-3'	Amplicon length (bp)	Accession no.
INFNG	F:	CACCAGCAAGCTGGAAGACT	163	NM_001081949.1
	R:	CCGGCCTCGAAATGGATTCT		
FOXP3	F:	AGATGCTGGCCGAGGTCAAC	149	XM_023633195.1
	R:	TGCGGAACTCGAACTCATCC		
IL-10	F:	ATAAGAGCAAGGCAGTGGAGC	77	NM_001082490.1
	R:	ACTCATGGCTTTGTAGACACC		
TGF beta	F:	ATTCCTGGCGCTACCTCAGT	197	NM_001081849.1
	R:	GCTGGAACTGAACCCGTTGAT		
LC3	F:	TTCTGAGACACAGTCGGAGC	128	XM_001493613.6
	R:	CTTTGTTCGAAGGTGTGGCG		
Beclin–1	F:	GATGCGTTATGCCCAGATGC	233	XM_014833759.1
	R:	AACGGCAGCTCCTCTGAAAT		
LAMP-2	F:	GCACCCCTGGGAAGTTCTTA	147	XM_014831347.1
	R:	ATCCAGCGAACACTCTTGGG		
PINK-1	F:	GCACAATGAGCCAGGAGCTA	298	XM_014737247.1
	R:	GGGGTATTCACGCGAAGGTA		
PARKIN	F:	TCCCAGTGGAGGTCGATTCT	218	XM_014858374.1
	R:	CCCTCCAGGTGTGTTCGTTT		
MFN	F:	AAGTGGCATTTTTCGGCAGG	217	XM_001495170.5
	R:	TCCATATGAAGGGCATGGGC		
FIS	F:	GGTGCGAAGCAAGTACAACG	118	XM_001504462.4
	R:	GTTGCCCACAGCCAGATAGA		
GAPDH	F:	GATGCCCCAATGTTTGTGA	250	XM_014866500.1
	R:	AAGCAGGGATGATGTTCTGG		
TNF-α	F:	ACAGAAAGCATGATCCGCGA	295	NM_013693.3
	R:	CTTGGTGGTTTGCTACGACG		
IL-1β	F:	TGCCACCTTTTGACAGTGATG	138	NM_008361.4
	R:	TGATGTGCTGCTGCGAGATT		
IL-6	F:	GAGGATACCACTCCCAACAGACC	141	NM_001314054.1
	R:	AAGTGCATCATCGTTGTTCATACA		
GAPDH	F:	TGCACCACCAACTGCTTAG	177	XM_017321385.1
	R:	GGATGCAGGGATGATGTTC		_

Table 1. Sequences of primers used in Reverse Transcription Polymerase Chain Reaction (RT-PCR).

*INFNG*—interferon gamma; *FOXP3*—forkhead box P3; *IL-10*—interleukin 10; *TGF beta*—tumor growth factor beta; *LC3*—microtubule-associated protein 1A/1B-light chain 3; *Beclin-1*; *LAMP-2*—Lysosome-associated membrane protein 2; *PINK-1*—PTEN-induced putative kinase 1; *PARKIN*—parkin ligase; *MFN*—mitofusin 1; *FIS*—mitochondrial fission 1 protein; *GAPDH*—glyceraldehyde 3-phosphate dehydrogenase; *TNF-α*—tumor necrosis factor alpha; *IL-1β*—interleukin 1 beta; *IL-6*—interleukin 6.

#### 2.7. ELISA Tests

Using ELISA amount of TNF- $\alpha$  (Mouse TNF- $\alpha$  Quantikine ELISA Kit, R&D Systems, Minneapolis, MN, USA), IL-6 (My Biosource, San Diego, CA, USA), IL-10 (Thermo Fisher Scientific, Carlsbad, CA, USA), and IL- $\beta$  (R&D Systems, Minneapolis, MN, USA) was evaluated. Procedures and calculations were carried out in accordance with the manufacturer's instruction. The absorbance was measured with a 96-well microplate reader (Epoch, BioTek) at 450 nm.

# 2.8. Statistical Analysis

Differences between experimental groups were estimated using ANOVA one way analysis of variance. Statistical analysis was conducted with GraphPad Prism 5 Software (La Jolla, CA, USA). Differences with probability of p < 0.05 were considered to be significant. Statistical significance was labelled with hash (#) when comparing to control group (CTRL) (ASCCTRL/PMBMCTRL) and asterisk (\*) when comparing to the EMS group (ASCEMS/PBMCEMS).

#### 3. Results

#### 3.1. Flow Cytometry Analysis of PBMCs

In order to investigate changes in blood cells number, peripheral mononuclear cells (PBMCs) were isolated from fresh blood using histopaque gradient. Next, PBMCs from control and EMS individuals were subjected to flow cytometry analysis. Representative graphs are shown in Figure 1A. The total number of lymphocytes was significantly lower in EMS horses (Figure 1B, p < 0.001) while CD<sub>4</sub><sup>+</sup> cells increased (Figure 1C, p < 0.001). On the other hand, percentage of CD<sub>4</sub><sup>+</sup> CD<sub>25</sub><sup>+</sup> regulatory cells was downregulated in EMS horses in comparison to healthy individuals (Figure 1D, p < 0.001).



**Figure 1.** Flow cytometry analysis of CD<sub>4</sub><sup>+</sup> CD<sub>25</sub><sup>+</sup> regulatory T cells. Representative graphs showing dot plots from flow cytometry analysis (**A**). Total number of lymphocytes was significantly decreased in equine metabolic syndrome (EMS) horses (**B**), while number of CD<sub>4</sub><sup>+</sup> cells increased (**C**). Furthermore, EMS horses were characterized by decreased number of T<sub>REG</sub> in circulating blood (**D**). Results expressed as mean  $\pm$  S.D. \*\*\* *p* < 0.001.

Next, PBMCs were co-cultured with ASC isolated from healthy and EMS individuals for 24 h. Using flow cytometry number of TREGS after co-culture was examined. Representative graphs are shown on Figure 2A–D. Quantification of obtained data revealed that co-culture of ASCCTRL with PBMCEMS, ASCEMS with PBMCEMS, and ASCEMS AZA/RES with PBMCEMS increased the number of CD4<sup>+</sup> CD25<sup>+</sup> T cell population (Figure 2E) in comparison to ASCCTRL with PBMCCTRL co-culture. Furthermore, ASCEMS AZA/RES co-cultured with PBMCEMS enhanced activation of TREG as significantly increased number of CD4<sup>+</sup> CD25<sup>+</sup> high cells number was noted in that group (Figure 2F). Interestingly, the expression of FOXP3 in PBMCS after co-culture was downregulated in all investigated groups in comparison to ASCCTRL cultured with PBMCCTRL (Figure 2G). What is more, we have also examined

expression of FOXP3 in ASC. Analysis revealed decreased gene expression in ASCCTRL cultured with ASCEMS and ASCEMS AZA/RES CO-cultured with PBMCEMS (Figure 2H).





**Figure 2.** Activation of CD<sub>4</sub><sup>+</sup> CD<sub>25</sub><sup>+</sup> regulatory T cells in co-culture with adipose-derived stem cells (ASC). Graphs are showing representative results of flow cytometry analysis (**A**–**D**). Peripheral blood mononuclear cells (PBMC) after co-culture with ASC were subjected for analysis of CD<sub>4</sub><sup>+</sup> CD<sub>25</sub><sup>+</sup> T cells population (**E**) and CD<sub>4</sub><sup>+</sup> CD<sub>25</sub> high T cells (**F**) using flow cytometry. Furthermore, using RT-PCR expression of FOXP3 was investigated both in PBMC (**G**) and ASC (**H**). Statistical

J. Clin. Med. **2018**, 7, 383

Significance was labelled with hash (#) when comparing to control group (ASCCTRL/PMBMCTRL) and asterisk (\*) when comparing to EMS group (ASCEMS/PBMCEMS). Results expressed as mean ± S.D. #, \*: *p* < 0.05; ###, \*\*\*: *p* < 0.001.

#### 3.2. Gene Expression After ASC-PBMC Co-Culture

After co-culture, both ASC and PBMC were lysed in TRIReagent in order to RNA isolation. Next, specimens were subjected for RT-PCR analysis. INFNG expression in PBMCs was downregulated in ASC<sub>CTRL</sub>/PBMC<sub>EMS</sub> (p < 0.001), ASC<sub>EMS</sub>/PBMC<sub>EMS</sub> (p < 0.001), and in ASC<sub>EMS AZA/RES</sub>/PBMC<sub>EMS</sub> (p < 0.001) in comparison to the control group (Figure 3A). A similar trend was observed in the expression of IL-10 (Figure 3B), while no differences were observed in the expression of TGF beta in investigated PBMCs (Figure 3C). For ASC, no expression of INFNG was found in ASC<sub>CTRL</sub>/PBMC<sub>EMS</sub>, while its expression was significantly up-regulated in ASC<sub>EMS</sub> co-cultured with PBMC<sub>EMS</sub> (p < 0.001) (Figure 3D). Furthermore, INFNG expression was downregulated (p < 0.05) in ASC<sub>EMS AZA/RES</sub> co-cultured with PBMC<sub>EMS</sub> (Figure 3D) in comparison to control group. IL-10 expression was downregulated in ASC<sub>EMS</sub> co-cultured with PBMC<sub>EMS</sub> (Figure 3E, p < 0.001), while it was increased in ASC<sub>EMS AZA/RES</sub> co-cultured with PBMC<sub>EMS</sub> (Figure 3E, p < 0.001). TGF beta expression (Figure 3F) was increased (p < 0.001) in all the investigated groups in comparison to control group (ASC<sub>CTRL</sub>/PBMC<sub>CTRL</sub>).



**Figure 3.** Gene expression profile in PBMCs and ASCs after co-culture. Using RT-PCR expression of INFNG (**A**), IL-10 (**B**), and tumor growth factor (TGF) beta (**C**) was examined in PBMCs after co-culture with ASCs. The mRNA levels of the same genes-INFNG (**D**), IL-10 (**E**), and TGF beta (**F**) was also investigated in ASCs. Statistical significance was labelled with hash (#) when comparing to control group (ASCCTRL/PMBMCTRL) and asterisk (\*) when comparing to the EMS group (ASCEMS/PBMCEMS). Results expressed as mean  $\pm$  S.D. ##, \*\* p < 0.01; ###, \*\*\* p < 0.001.

#### 3.3. Cytokines, NO, and SOD Amount after ASC-PBMC Co-Culture

In order to perform the assays culture media after co-culture was collected and analysed. Using ELISA, IL-6, IL-10, and IL-1 $\beta$  secretion was examined. Obtained data indicated an increased amount of IL-6 (Figure 4A) in all experimental groups in comparison to control (p < 0.001). Interestingly, no differences in the levels of, IL-10 (Figure 4B) neither IL-1 $\beta$  (Figure 4C) was observed. Furthermore, using Griess reagent amount of NO in culture media was established (Figure 4D), however no statistically significant differences were found between investigated groups. SOD activity was ameliorated in all experimental groups when compared to the control one (Figure 4E, p < 0.001).



**Figure 4.** Cytokines, nitric oxide (NO), and superoxide dismutase SOD amounts evaluated after coculture of ASCs with PBMCs. Culture media after co-culture was collected and subjected for analysis. Using ELISA (**A**) amount of IL-6 (**A**), IL-10 (**B**) and IL-1 $\beta$  (**C**) was evaluated. Using spectrophotometric assays NO (**D**) and SOD (**E**) levels were investigated. Statistical significance was labelled with hash (#) when comparing to control group (ASCCTRL/PMBMCTRL) and asterisk (\*) when comparing to the EMS group (ASCEMS/PBMCEMS). Results expressed as mean ± S.D. ###, \*\*\* *p* < 0.001.

## 3.4. Evaluation of Autophagy-Related Genes after ASC-PBMC Co-Culture

In order to evaluate the levels of autophagy, expression of LC3, Beclin-1 and LAMP2 was evaluated in both ASC and PBMC after co-culture for 24 h. LC3 expression was significantly downregulated in PMBC<sub>EMS</sub> after co-culture with ASC<sub>EMS</sub> (Figure 5A, p < 0.05), while no differences were noted in the expression of Beclin-1 in investigated PBMCs (Figure 5B). LAMP2 expression was significantly increased in ASC<sub>CTRL</sub>/PBMC<sub>EMS</sub> and ASC<sub>EMS</sub> AZA/RE5/PBMC<sub>EMS</sub> groups (Figure 5C, p < 0.001). In ASC, no differences were found in the expression of LC3 (Figure 5D). Beclin-1 mRNA was downregulated (Figure 5E) in ASC<sub>CTRL</sub> cultured with PBMC<sub>EMS</sub> and in ASC<sub>EMS</sub> co-cultured with PBMC<sub>EMS</sub> were characterized by increased Beclin-1 expression (p < 0.001) in comparison to ASC<sub>EMS</sub> that are co-cultured with PBMC<sub>EMS</sub>. Similar trend was observed in the expression of LAMP2 (Figure 5F) in ASC<sub>EMS</sub>.



**Figure 5.** Evaluation of autophagic genes after co-culture of ASCs with PBMCs. Using RT-PCR expression of LC3 (**A**), Beclin-1 (**B**), and LAMP-2 in PBMCs were analysed (**C**). Similarly mRNA levels of LC3 (**D**), Beclin-1 (**E**) and LAMP-2 (**F**) were investigated in ASC. Statistical significance was labelled with hash (#) when comparing to control group (ASC<sub>CTRL</sub>/PMBM<sub>CTRL</sub>) and asterisk (\*) when comparing to EMS group (ASC<sub>EMS</sub>/PBMC<sub>EMS</sub>). Results expressed as mean  $\pm$  S.D. # p < 0.05; ## p < 0.01; ###, \*\*\* p < 0.001.

#### 3.5. Evaluation of Mitophagy-Related Genes after Co ASC-PBMC Co-Culture

In order to evaluate mitophagy, cells were subjected for RT-PCR analysis. Expression of following genes was examined: PINK-1, PARKIN, MFN, and FIS. PINK-1 expression was upregulated (p < 0.001) in PBMCems co-cultured with ASCems and ASCems AZA/RES (Figure 6A). No statistically significant differences were observed in the expression of PARKIN between the investigated groups (Figure 6B). MFN expression in PBMC was downregulated in experimental groups in comparison to control (ASCCTR/PBMCCTRL) (Figure 6C). FIS expression was downregulated in PBMC co-cultured with ASCEMS and ASCEMS AZA/RES (Figure 6D, p < 0.01 and p < 0.001, respectively). The FIS/MNF ratio was increased in all investigated groups however most significantly in PBMCs co-cultured with ASCEMS AZA/RES (Figure 6E, p < 0.001). In ASC, PINK-1 expression was upregulated in ASCEMS cells co-cultured with PBMCEMS (p < 0.001) while decreased in ASCEMS AZA/RES (p < 0.001) (Figure 6F). PARKIN expression was only up-regulated in ASCEMS co-cultured with PBMCEMS (Figure 6G,  $p < 10^{-10}$ 0.05). MFN mRNA levels were decreased in ASCEMS co-cultured with PBMCEMS and in ASCEMS AZA/RES co-cultured with PBMCEMS (Figure 6H, p < 0.001). FIS expression was significantly increased in ASCCTRL that was co-cultured with PBMCEMS and in ASCEMS AZA/RES co-cultured with PBMCEMS (Figure 6I, p < 0.001). FIS/MFN ratio was significantly increased in all experimental groups in comparison to control (Figure 6J, p < 0.001).





**Figure 6.** Evaluation of mitophagy-related genes after co-culture of ASCs with PBMCs. After coculture expression of PINK-1 (**A**), PARKIN (**B**), MFN (**C**), and FIS (**D**) in PBMCs was evaluated using RT-PCR. Furthermore, the ratio of FIS/MNF (**E**) was calculated based on relative expression of both genes. The same genes: PINK-1 (**F**), PARKIN (**G**), MFN (H), and FIS (**I**) mRNA levels were established for ASCs. Similarly, ratio of FIS/MNF expression was calculated (**J**). Statistical significance was labelled with hash (#) when comparing to control group (ASC<sub>CTRL</sub>/PMBM<sub>CTRL</sub>) and asterisk (\*) when comparing to the EMS group (ASC<sub>EMS</sub>/PBMC<sub>EMS</sub>). Results expressed as mean ± S.D. #, \* p < 0.05; ## p <0.01; ###, \*\*\* p < 0.001.

#### 3.6. Co-Culture of ASC with RAW264.7 Macrophages

In order to evaluate the immunomodulatory properties of ASC they were incubated with LPSstimulated RAW264.7 macrophages for 24 h. Next, cells and culture media were subjected for further analysis. ELISA for TNF- $\alpha$  revealed its decreased levels in ASCEMS AZA/RES group in comparison to untreated ASCEMS (Figure 7A, p < 0.01). NO amount was increased in ASCEMS (p < 0.001, Figure 7B), however, in the ASCEMS AZA/RES group its levels were decreased (p < 0.001). IL-1 $\beta$  expression (Figure 7C) was downregulated in both ASCEMS and ASCEMS AZA/RES (p < 0.05 and p < 0.001 respectively). IL-6 expression (Figure 7D) was upregulated in ASCEMS in comparison to ASCCTRL (p < 0.01) while downregulated (p < 0.01) in ASCEMS AZA/RES when comparing to untreated cells. TNF- $\alpha$  mRNA level (Figure 7E) was increased (p < 0.001) in both ASCEMS and ASCEMS AZA/RES while comparing to ASCCTRL. However its expression was decreased in ASCEMS AZA/RES in comparison to ASCEMS (p < 0.001).





**Figure 7.** Anti-inflammatory properties of ASC s cultured with RAW 264.7 macrophages. ASCs were co-cultured with LPS-treated macrophages in order to evaluate their immunomodulatory properties. After co-culture culture media was collected and subjected for TNF- $\alpha$  (**A**) analysis with ELISA test. Using Griess reagent amount of NO was examined (**B**). RT-PCR was performed to investigate expression of IL-1 $\beta$  (**C**), IL-6 (**D**), and TNF- $\alpha$  (**E**). Statistical significance was labelled with hash (#) when comparing to control group (LPS+ASCCTRL) and asterisk (\*) when comparing to EMS group (LPS+ASCEMS). Results expressed as mean ± S.D. #, p < 0.05; ##, \*\* p < 0.01; ###, \*\*\* p < 0.001.

# 3.7. Auto- and Mitophagy after ASC-RAW264.7 Co-Culture

In order to evaluate levels of autophagy and mitophagy in ASC after co-culture with macrophages following genes expression was examined with RT-PCR: Beclin-1, LAMP-2, PINK-1, PARKIN, MFN, and FIS. No statistically significant differences were noted in the expression of Beclin-1 between investigated groups (Figure 8A). LAMP2 mRNA levels were increased in ASC<sub>EMS</sub> in comparison to control cells (Figure 8B, p < 0.05). Furthermore, no significant differences were found in the expression of PINK-1 between investigated groups (Figure 8C). PARKIN expression was significantly upregulated in ASC<sub>EMS</sub> and ASC<sub>EMS</sub> AZA/RES while comparing to ASC<sub>CTRL</sub> (Figure 8D, p < 0.01). MFN expression (Figure 8E) was increased in ASC<sub>EMS</sub> (p < 0.001) and ASC<sub>EMS</sub> AZA/RES (p < 0.05) in comparison to control cells. Similar trend was observed regarding FIS expression (Figure 8F) as it was increased in ASC<sub>EMS</sub> AZA/RES (p < 0.01).



**Figure 8.** Auto- and mitophagy in ASCs co-cultured with RAW264.7 macrophages. After co-culture, ASC were collected and subjected for RT-PCR. Expression of Beclin-1 (**A**), LAMP-2 (**B**), PINK-1 (**C**), PARKIN (**D**), MFN (**E**), and FIS (**F**) was evaluated. Statistical significance was labelled with hash (#) when comparing to control group (ASCCTRL) and asterisk (\*) when comparing to EMS group (ASCEMS). Results expressed as mean  $\pm$  S.D. #, \* *p* < 0.05; ## *p* < 0.01; ### *p* < 0.001.

#### 4. Discussion

In our previous study, we reported that the treatment of ASCEMS with AZA/RES reversed their aged phenotype and rejuvenated them, so that their physiological properties were comparable to those observed in ASCCTRL. In the present study, we have investigated immunomodulatory properties of these cells in co-culture with PBMCs and RAW264.7 macrophages. We have found for the first time that ASCEMS and ASCEMS that are treated with AZA/RES induced and increased Treg activity and caused dynamic alternations in the cytokine expression pattern.

Systemic obesity and metabolic syndrome-related abnormalities in the peripheral blood T-cell compartment are not well characterized. In the current study, we have evaluated for the first time the peripheral blood T-cell compartment in healthy and EMS horses. A large body of evidence indicates a pathological role of CD4<sup>+</sup> T cells in obesity and insulin resistance. We have discovered an increased number of CD4<sup>+</sup> cells in EMS individuals. This is consistent with the study that was conducted by van der Weerd et al. [21], who discovered that CD4+ T-cell number correlated positively with fasting insulin levels in obese patients. A study performed by Shirakawa et al. [22] demonstrated elevated levels of activated CD4<sup>+</sup> T cells in the visceral adipose tissue of obese mice. It has been suggested that obesity triggers major histocompatibility complex (MHC) class II expression on adipocytes and activates CD4<sup>+</sup> T cells to initiate inflammation in adipose tissue. This is in line with our previous data, because we have shown increased inflammation of adipose tissue in EMS individuals [23]. Tregs belong to a small subset of T lymphocytes, constituting about 5–20% of CD4<sup>+</sup>. However, they are believed to be important players in preventing inflammatory responses and tissue damage [24]. Furthermore, they are characterized by high-level expression of a forkhead/winged-helix transcription factor, FOXP3. In the present study, we have observed significantly decreased Treg count in the blood of EMS horses, which may be the cause of prolonged inflammation and insulin resistance in these subjects. It was shown that Treg cells could suppress Th1, Th2, and Th17 response in order to enhance insulin resistance. Furthermore, the number of Tregs was also decreased in patients with type 2 diabetes and metabolic syndrome [25,26], while their high number was recorded in lean mice [27]. Thus, Tregs may become a valuable therapeutic tool in EMS by limiting proinflammatory milieu and increasing insulin sensitivity. Interestingly, we observed that ASCEMS treated with AZA/RES increased the number of Tregs in co-culture with PBMCs. Hence, it is likely that after the application of these cells to EMS individuals, the number of circulating Tregs in their blood may increase. Interestingly, mRNA levels of FOXP3 in ASCEMS treated with AZA/RES were decreased. However, it was shown that FOXP3-decreased MSCs retained their immunosuppressive properties [28].

It has been shown that cytokines produced by immune cells modulate MSC fate and function leading to the release of immunomodulatory and growth factors [29,30]. After PBMC co-culture with ASCs, we have investigated mRNA levels of selected cytokines. Interestingly, INFNG expression in PBMCs from EMS horses was significantly decreased in comparison to the control group. The precise mechanisms of these phenomena remain unclear. However, a decreased response of INFNG that is caused by PBMC was also observed in patients with Graves' disease, Hashimoto's thyroiditis, and rheumatoid arthritis [31]. We hypothesize that defects in INFNG synthesis may result from changes in ASCEMS response to different stimuli and might be related to disease activity. Interestingly, both IL-10 and TGF beta levels were elevated in ASCEMS treated with AZA/RES. It was shown that the increased production of IL-10 by MSCs inhibited Th17 differentiation, an important proinflammatory CD4+ T cell subtype that is associated with type 2 diabetes [32]. On the other hand, it was demonstrated that TGF beta is an essential factor by which MSCs activate Tregs [33]. It was observed in the co-culture of ASCEMS pre-treated with AZA/RES with PBMCs that the increased TGF beta production by ASCEMS treated with AZA/RES correlated with the increased number of Tregs. Total level of IL-6 measured in the supernatant by ELISA was increased in both ASCEMS and ASCEMS treated with AZA/RES. This may be correlated with the fact that elevated serum levels of IL-6 are recognized as an early and representative marker in metabolic syndrome pathogenesis [34].

Autophagy is recognized as a process that allows for the degradation of cellular components by the lysosomes. Previous studies have indicated that autophagy plays a role in lipotoxicity-induced apoptosis and inflammation [35]. However, its function in inflammatory response of PBMCs co-cultured with ASCs is not fully understood. We observed that LAMP-2 expression was significantly elevated in PBMCs co-cultured with ASCEMS after AZA/RES pre-treatment. LAMP-2 is a protein that is necessary for the maturation of autophagosomes and cargo removal. This indicates that ASCEMS after AZA/RES treatment induces autophagy in PBMCs. Interestingly, LAMP-2 down-regulation in PBMCs cultured with ASCEMS may be a novel mechanism that connects obesity and inflammation in EMS horses. It was shown that reduced autophagy in PBMCs in type 2 diabetes patients was correlated with an enhanced inflammation [36]. Therefore, it is tempting to speculate that rejuvenated ASCs with AZA/RES will affect the physiological properties of PBMCs after clinical application in EMS individuals by triggering autophagy, and, in consequence, diminishing the inflammatory state of the animal body.

Mitophagy involves the selective engulfment of impaired mitochondria into autophagosomes and it serves as a quantity and quality control mechanism [37]. Mitophagy is controlled by different genes, including PTEN-induced putative kinase 1 (PINK1), PARKIN, microtubule-associated protein light chain 3 (LC3), lysosome-associated membrane protein-2 (LAMP-2), mitofusin2 (MFN2), and mitochondrial fission protein (FIS) [38]. Our study is the first report demonstrating that co-culture of PBMCs with AZA/RES-treated ASCEMS induces mitophagy in PBMCs. Thus, it reverses the changes observed in PBMCs from type 2 diabetic patients, who are characterized by down-regulation of MFN2, PINK1, PARKIN, and LAMP-2 genes at the mRNA and protein level. The observed increased mitophagy enables elimination of dysfunctional mitochondria, thereby preventing their accumulation in cells and exacerbation of mitochondrial oxidative stress induced by hyperglycemia. Mitochondrial fission results in the formation of small individual mitochondria, while interconnected networks of these organelles are generated during fusion. In the present study, we observed the upregulation of fission in PBCMs and co-cultured ASCEMS treated with AZA/RES, which indicated increased mitophagy. Studies have demonstrated that the loss of mitophagy can lead to the accumulation of ROS and induce immune signaling pathways leading to the release of proinflammatory cytokines [39]. Thus, the up-regulation of mitophagy observed in the experimental group may contribute to the shift towards anti-inflammatory phenotype of these cells. Mitophagy may be a crucial factor controlling inflammatory response in immune cells.

We co-cultured AZA/RES-treated ASCs with LPS-stimulated RAW264.7 macrophages to further investigate their immunomodulatory properties. ASCs isolated from EMS individuals were characterized by increased expression of NO, IL-6, and TNF- $\alpha$ . On the other hand, ASCEMS pre-treated with AZA/RES displayed anti-inflammatory properties, as decreased TNF- $\alpha$ , NO, and IL-6 levels were observed in these cells in comparison to their untreated counterparts. This phenomenon is in good agreement with the results of Wang et al. [40], who observed that the combined treatment with mouse bone marrow MSCs and resveratrol suppressed proinflammatory cytokines (IFN- $\gamma$ , TNF- $\alpha$ ) and increased anti-inflammatory cytokines (IL-4, IL-10) secretion in experimental autoimmune encephalomyelitis. Anti-inflammatory properties of resveratrol have been demonstrated in pancreatitis [41], arthritis [42], and experimental colitis [43]. Wang et al. discovered that RES prevented the suppression of Treg production, oxidative stress, and inflammation of mice that are prone or resistant to high fat diet-induced obesity [44]. Moreover, similarly to PBMCs-ASCs coculture, ASCEMS pre-treated with AZA/RES were characterized by increased mitophagy when cocultured with RAW264.7 macrophages. Thus, we hypothesize that these mechanisms are mainly responsible for immune response modulation in ASCs treated with AZA/RES.

# 5. Conclusions

In summary, our study demonstrated that ASCEMS treated with a combination of AZA/RES displayed enhanced anti-inflammatory properties and were able to regulate and activate Tregs-related anti-inflammatory response. These observations correlate with the occurrence of mitophagy and mitochondrial fission, both in ASCs and immune cells. We postulate that the anti-inflammatory phenotype of these cells requires the modulation of mitochondrial dynamics. Our results provide a potential interventional strategy for managing inflammation in EMS horses by the application of AZA/RES-rejuvenated ASCs.

**Author Contributions:** K.M., M.R. and K.K. designed the research. K.K., A.Ś. and A.S.W. conducted the research. K.M., K.K. and M.R. analyzed data. K.M. and K.K. wrote the paper, K.K., A.Ś. and A.S.W. prepared the figures. K.M. contributed reagents/materials/analysis tools. All authors read and approved the final manuscript.

**Funding:** This project is financed in the framework of grant entitled "Modulation mitochondrial metabolism and dynamics and targeting DNA methylation of adipose derived mesenchymal stromal stem cell (ASC) using RES and 5-azacytydin as a therapeutic strategy in the course of EMS." (grant no. 2016/21/B/NZ7/01111) financed by The National Science Centre in Poland. The publication is supported by Wroclaw Centre of Biotechnology, programme the Leading National Research Centre (KNOW) for years 2014–2018.

Conflicts of Interest: The authors declare that there is no conflict of interest.

#### References

- Yu, H.; Côté, P.; Shearer, H.M.; Wong, J.J.; Sutton, D.A.; Randhawa, K.A.; Varatharajan, S.; Southerst, D.; Mior, S.A.; Ameis, A.; et al. Effectiveness of passive physical modalities for shoulder pain: Systematic review by the Ontario protocol for traffic injury management collaboration. *Phys. Ther.* 2015, *95*, 306–318, doi:10.2522/ptj.20140361.
- Castillo, D.T.; Lacefield, K.; C'de Baca, J.; Blankenship, A.; Qualls, C. Effectiveness of group-delivered cognitive therapy and treatment length in women veterans with PTSD. *Behav. Sci. (Basel)* 2014, *4*, 31–41, doi:10.3390/bs4010031.
- 3. Cordeiro-Spinetti, E.; de Mello, W.; Trindade, L.S.; Taub, D.D.; Taichman, R.S.; Balduino, A. Human bone marrow mesenchymal progenitors: Perspectives on an optimized in vitro manipulation. *Front. Cell Dev. Biol.* **2014**, *2*, doi:10.3389/fcell.2014.00007.
- 4. Machado, C. de V.; Telles, P.D. da S.; Nascimento, I.L.O. Immunological characteristics of mesenchymal stem cells. *Rev. Bras. Hematol. Hemoter.* **2013**, *35*, 62–67, doi:10.5581/1516-8484.20130017.
- Chan, J.L.; Tang, K.C.; Patel, A.P.; Bonilla, L.M.; Pierobon, N.; Ponzio, N.M.; Rameshwar, P. Antigenpresenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferonγ. *Blood* 2006, 107, 4817–4824, doi:10.1182/blood-2006-01-0057.
- 6. Puissant, B.; Barreau, C.; Bourin, P.; Clavel, C.; Corre, J.; Bousquet, C.; Taureau, C.; Cousin, B.; Abbal, M.; Laharrague, P.; et al. Immunomodulatory effect of human adipose tissue-derived adult stem cells:

Comparison with bone marrow mesenchymal stem cells. *Br. J. Haematol.* **2005**, *129*, 118–129, doi:10.1111/j.1365-2141.2005.05409.x.

- 7. Glennie, S.; Soeiro, I.; Dyson, P.J.; Lam, E.W.-F.; Dazzi, F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. *Blood* 2005, *105*, 2821–2827, doi:10.1182/blood-2004-09-3696.
- Selmani, Z.; Naji, A.; Zidi, I.; Favier, B.; Gaiffe, E.; Obert, L.; Borg, C.; Saas, P.; Tiberghien, P.; Rouas-Freiss, N.; et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. *Stem Cells* 2008, 26, 212–222, doi:10.1634/stemcells.2007-0554.
- 9. Marycz, K.; Kornicka, K.; Szlapka-Kosarzewska, J.; Weiss, C. Excessive endoplasmic reticulum stress correlates with impaired mitochondrial dynamics, mitophagy and apoptosis, in liver and adipose tissue, but not in Muscles in EMS horses. *Int. J. Mol. Sci.* **2018**, *19*, doi:10.3390/ijms19010165.
- 10. Holbrook, T.C.; Tipton, T.; McFarlane, D. Neutrophil and cytokine dysregulation in hyperinsulinemic obese horses. *Vet. Immunol. Immunopathol.* **2012**, *145*, 283–289, doi:10.1016/j.vetimm.2011.11.013.
- 11. Burns, T.A.; Geor, R.J.; Mudge, M.C.; McCutcheon, L.J.; Hinchcliff, K.W.; Belknap, J.K. Proinflammatory cytokine and chemokine gene expression profiles in subcutaneous and visceral adipose tissue depots of insulin-resistant and insulin-sensitive light breed horses. *J. Vet. Intern. Med.* **2010**, *24*, 932–939, doi:10.1111/j.1939-1676.2010.0551.x.
- 12. Vick, M.M.; Murphy, B.A.; Sessions, D.R.; Reedy, S.E.; Kennedy, E.L.; Horohov, D.W.; Cook, R.F.; Fitzgerald, B.P. Effects of systemic inflammation on insulin sensitivity in horses and inflammatory cytokine expression in adipose tissue. *Am. J. Vet. Res.* **2008**, *69*, 130–139, doi:10.2460/ajvr.69.1.130.
- 13. Marycz, K.; Kornicka, K.; Basinska, K.; Czyrek, A. Equine metabolic syndrome affects viability, senescence, and stress factors of equine adipose-derived mesenchymal stromal stem cells: New insight into EqASCs isolated from EMS horses in the context of their aging. *Oxid. Med. Cell. Longev.* **2016**, 2016, 1–17, doi:10.1155/2016/4710326.
- 14. Marycz, K.; Kornicka, K.; Grzesiak, J.; Śmieszek, A.; Szłapka, J. Macroautophagy and Selective Mitophagy Ameliorate Chondrogenic Differentiation Potential in Adipose Stem Cells of Equine Metabolic Syndrome: New Findings in the Field of Progenitor Cells Differentiation. Available online: https://www.hindawi.com/journals/omcl/2016/3718468/ (accessed on 27 July 2017).
- Marycz, K.; Kornicka, K.; Marędziak, M.; Golonka, P.; Nicpoń, J. Equine metabolic syndrome impairs adipose stem cells osteogenic differentiation by predominance of autophagy over selective mitophagy. *J. Cell. Mol. Med.* 2016, 20, 2384–2404, doi:10.1111/jcmm.12932.
- Kornicka, K.; Marycz, K.; Marędziak, M.; Tomaszewski, K.A.; Nicpoń, J. The effects of the DNA methyltranfserases inhibitor 5-Azacitidine on ageing, oxidative stress and DNA methylation of adipose derived stem cells. J. Cell. Mol. Med. 2017, 21, 387–401, doi:10.1111/jcmm.12972.
- 17. Kornicka, K.; Nawrocka, D.; Lis-Bartos, A.; Marędziak, M.; Marycz, K. Polyurethane–polylactide-based material doped with resveratrol decreases senescence and oxidative stress of adipose-derived mesenchymal stromal stem cell (ASCs). *RSC Adv.* **2017**, *7*, 24070–24084, doi:10.1039/C7RA02334K.
- 18. Kuballa, P.; Nolte, W.M.; Castoreno, A.B.; Xavier, R.J. Autophagy and the immune system. *Annu. Rev. Immunol.* **2012**, *30*, 611–646, doi:10.1146/annurev-immunol-020711-074948.
- 19. Marycz, K.; Weiss, C.; Śmieszek, A.; Kornicka, K. Evaluation of oxidative stress and mitophagy during adipogenic differentiation of adipose-derived stem cells isolated from equine metabolic syndrome (EMS) horses. *Stem Cells Int.* **2018**, 2018, doi:10.1155/2018/5340756.
- 20. Chomczynski, P.; Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction. *Anal. Biochem.* **1987**, *162*, 156–159, doi:10.1006/abio.1987.9999.
- 21. van der Weerd, K.; Dik, W.A.; Schrijver, B.; Schweitzer, D.H.; Langerak, A.W.; Drexhage, H.A.; Kiewiet, R.M.; van Aken, M.O.; van Huisstede, A.; van Dongen, J.J.M.; et al. Morbidly obese human subjects have increased peripheral blood CD4+ T cells with skewing toward a Treg- and Th2-dominated phenotype. *Diabetes* **2012**, *61*, 401–408, doi:10.2337/db11-1065.
- Shirakawa, K.; Yan, X.; Shinmura, K.; Endo, J.; Kataoka, M.; Katsumata, Y.; Yamamoto, T.; Anzai, A.; Isobe, S.; Yoshida, N.; et al. Obesity accelerates T cell senescence in murine visceral adipose tissue. *J. Clin. Investig.* 2016, *126*, 4626–4639, doi:10.1172/JCI88606.
- 23. Basinska, K.; Marycz, K.; Śmieszek, A.; Nicpoń, J. The production and distribution of IL-6 and TNF-*α* in subcutaneous adipose tissue and their correlation with serum concentrations in Welsh ponies with equine metabolic syndrome. *J. Vet. Sci.* **2015**, *16*, 113–120, doi:10.4142/jvs.2015.16.1.113.

- 24. Zheng, Y.; Rudensky, A.Y. Foxp3 in control of the regulatory T cell lineage. *Nat. Immunol.* **2007**, *8*, 457–462, doi:10.1038/ni1455.
- 25. Jagannathan-Bogdan, M.; McDonnell, M.E.; Shin, H.; Rehman, Q.; Hasturk, H.; Apovian, C.M.; Nikolajczyk, B.S. Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes. *J. Immunol.* **2011**, *186*, 1162–1172, doi:10.4049/jimmunol.1002615.
- 26. Wagner, N.-M.; Brandhorst, G.; Czepluch, F.; Lankeit, M.; Eberle, C.; Herzberg, S.; Faustin, V.; Riggert, J.; Oellerich, M.; Hasenfuss, G.; et al. Circulating regulatory T cells are reduced in obesity and may identify subjects at increased metabolic and cardiovascular risk. *Obesity (Silver Spring)* **2013**, *21*, 461–468, doi:10.1002/oby.20087.
- 27. Feuerer, M.; Herrero, L.; Cipolletta, D.; Naaz, A.; Wong, J.; Nayer, A.; Lee, J.; Goldfine, A.B.; Benoist, C.; Shoelson, S.; et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. *Nat. Med.* **2009**, *15*, 930–939, doi:10.1038/nm.2002.
- 28. Sundin, M.; D'arcy, P.; Johansson, C.C.; Barrett, A.J.; Lönnies, H.; Sundberg, B.; Nava, S.; Kiessling, R.; Mougiakakos, D.; Le Blanc, K. Multipotent mesenchymal stromal cells express FoxP3: A marker for the immunosuppressive capacity? *J. Immunother*. **2011**, *34*, 336–342, doi:10.1097/CJI.0b013e318217007c.
- 29. Leto Barone, A.A.; Khalifian, S.; Lee, W.P.A.; Brandacher, G. Immunomodulatory effects of adiposederived stem cells: Fact or fiction? *Biomed. Res. Int.* 2013, 2013, doi:10.1155/2013/383685.
- Abdi, R.; Fiorina, P.; Adra, C.N.; Atkinson, M.; Sayegh, M.H. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. *Diabetes* 2008, 57, 1759–1767, doi:10.2337/db08-0180.
- 31. Matsubayashi, S.; Akasu, F.; Kasuga, Y.; Snow, K.; Keystone, E.; Volpé, R. In vitro production of interferongamma by peripheral blood from patients with Graves' disease, Hashimoto's thyroiditis and rheumatoid arthritis. *Clin. Exp. Immunol.* **1990**, *82*, 63–68.
- Zhang, C.; Xiao, C.; Wang, P.; Xu, W.; Zhang, A.; Li, Q.; Xu, X. The alteration of Th1/Th2/Th17/Treg paradigm in patients with type 2 diabetes mellitus: Relationship with diabetic nephropathy. *Hum. Immunol.* 2014, 75, 289–296, doi:10.1016/j.humimm.2014.02.007.
- 33. English, K.; Ryan, J.M.; Tobin, L.; Murphy, M.J.; Barry, F.P.; Mahon, B.P. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. *Clin. Exp. Immunol.* **2009**, *156*, 149–160, doi:10.1111/j.1365-2249.2009.03874.x.
- 34. Bao, P.; Liu, G.; Wei, Y. Association between IL-6 and related risk factors of metabolic syndrome and cardiovascular disease in young rats. *Int. J. Clin. Exp. Med.* **2015**, *8*, 13491–13499.
- 35. Levine, B.; Mizushima, N.; Virgin, H.W. Autophagy in immunity and inflammation. *Nature* **2011**, *469*, 323–335, doi:10.1038/nature09782.
- Alizadeh, S.; Mazloom, H.; Sadeghi, A.; Emamgholipour, S.; Golestani, A.; Noorbakhsh, F.; Khoshniatnikoo, M.; Meshkani, R. Evidence for the link between defective autophagy and inflammation in peripheral blood mononuclear cells of type 2 diabetic patients. *J. Physiol. Biochem.* 2018, 1–11, doi:10.1007/s13105-018-0624-2.
- 37. Hirota, Y.; Kang, D.; Kanki, T. The physiological role of mitophagy: New insights into phosphorylation events. *Int. J. Cell Biol.* **2012**, 2012, 354914, doi:10.1155/2012/354914.
- 38. Ding, W.-X.; Yin, X.-M. Mitophagy: Mechanisms, pathophysiological roles, and analysis. *Biol. Chem.* **2012**, 393, 547–564, doi:10.1515/hsz-2012-0119.
- 39. Harris, J.; Deen, N.; Zamani, S.; Hasnat, M.A. Mitophagy and the release of inflammatory cytokines. *Mitochondrion* **2017**, doi:10.1016/j.mito.2017.10.009.
- 40. Wang, D.; Li, S.-P.; Fu, J.-S.; Bai, L.; Guo, L. Resveratrol augments therapeutic efficiency of mouse bone marrow mesenchymal stem cell-based therapy in experimental autoimmune encephalomyelitis. *Int. J. Dev. Neurosci.* **2016**, *49*, 60–66, doi:10.1016/j.ijdevneu.2016.01.005.
- 41. Ma, Z.-H.; Ma, Q.-Y.; Wang, L.-C.; Sha, H.-C.; Wu, S.-L.; Zhang, M. Effect of resveratrol on peritoneal macrophages in rats with severe acute pancreatitis. *Inflamm. Res.* **2005**, *54*, 522–527, doi:10.1007/s00011-005-1388-z.
- 42. Elmali, N.; Baysal, O.; Harma, A.; Esenkaya, I.; Mizrak, B. Effects of resveratrol in inflammatory arthritis. *Inflammation* **2007**, *30*, 1–6, doi:10.1007/s10753-006-9012-0.

- Larrosa, M.; Yañéz-Gascón, M.J.; Selma, M.V.; González-Sarrías, A.; Toti, S.; Cerón, J.J.; Tomás-Barberán, F.; Dolara, P.; Espín, J.C. Effect of a low dose of dietary resveratrol on colon microbiota, inflammation and tissue damage in a DSS-induced colitis rat model. *J. Agric. Food Chem.* 2009, *57*, 2211–2220, doi:10.1021/jf803638d.
- 44. Wang, B.; Sun, J.; Li, X.; Zhou, Q.; Bai, J.; Shi, Y.; Le, G. Resveratrol prevents suppression of regulatory T-cell production, oxidative stress, and inflammation of mice prone or resistant to high-fat diet-induced obesity. *Nutr. Res.* **2013**, *33*, 971–981, doi:10.1016/j.nutres.2013.07.016.



© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).